During the last session, Immuneering Corp (NASDAQ:IMRX)’s traded shares were 0.34 million, with the beta value of the company hitting -0.35. At the end of the trading day, the stock’s price was $2.10, reflecting an intraday loss of -0.47% or -$0.01. The 52-week high for the IMRX share is $8.89, that puts it down -323.33 from that peak though still a striking 52.38% gain since the share price plummeted to a 52-week low of $1.00. The company’s market capitalization is $65.21M, and the average intraday trading volume over the past 10 days was 0.43 million shares, and the average trade volume was 5.45 million shares over the past three months.
Immuneering Corp (IMRX) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.67. IMRX has a Sell rating from 0 analyst(s) out of 3 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 3 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.42.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Immuneering Corp (NASDAQ:IMRX) trade information
Immuneering Corp (IMRX) registered a -0.47% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -0.47% in intraday trading to $2.10, hitting a weekly high. The stock’s 5-day price performance is 16.67%, and it has moved by -2.33% in 30 days. Based on these gigs, the overall price performance for the year is -71.85%. The short interest in Immuneering Corp (NASDAQ:IMRX) is 2.05 million shares and it means that shorts have 1.19 day(s) to cover.
The consensus price target of analysts on Wall Street is $13, which implies an increase of 83.85% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $3 and $41 respectively. As a result, IMRX is trading at a discount of -1852.38% off the target high and -42.86% off the low.
Immuneering Corp (IMRX) estimates and forecasts
Statistics show that Immuneering Corp has underperformed its competitors in share price, compared to the industry in which it operates. Immuneering Corp (IMRX) shares have gone up 51.08% during the last six months, with a year-to-date growth rate less than the industry average at 1.60% against 17.90. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to grow 18.46% this quarter and then jump 16.33% in the quarter after that.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -57.97%. While earnings are projected to return 2.30% in 2024.
IMRX Dividends
Immuneering Corp is due to release its next quarterly earnings in December. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Immuneering Corp (NASDAQ:IMRX)’s Major holders
Immuneering Corp insiders own 29.12% of total outstanding shares while institutional holders control 30.11%, with the float percentage being 42.48%. CITADEL ADVISORS LLC is the largest shareholder of the company, while 65.0 institutions own stock in it. As of 2024-06-30, the company held over 1.88 million shares (or 6.4083% of all shares), a total value of $2.41 million in shares.
The next largest institutional holding, with 1.07 million shares, is of VANGUARD GROUP INC’s that is approximately 3.6442% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $1.37 million.
Also, the Mutual Funds coming in first place with the largest holdings of Immuneering Corp (IMRX) shares are Vanguard Total Stock Market Index Fund and Price (T.Rowe) Health Sciences Fund . Data provided on Jun 30, 2024 indicates that Vanguard Total Stock Market Index Fund owns about 736.19 shares. This amounts to just over 2.37 percent of the company’s overall shares, with a $1.55 million market value. The same data shows that the other fund manager holds slightly less at 558.38, or about 1.80% of the stock, which is worth about $1.17 million.
